Matrix Laboratories News Today

Kotak is lending $150 million (₹1,250 crore) under a mezzanine debt facility to Prasad at 18-20% and arranging an additional $300 million from other lenders including Edelweiss Domestic Performing Credit Fund, two people close to the development said. The Edelweiss fund is lending the money, a senior debt facility, at 10-11%.

The fund plans to provide a $150 million mezzanine debt facility at 18-20% and arrange another $300 million from other lenders to finance the acquisition, said a person in the know. "The funding cost could vary by the instrument where the blend-in cost could be 14-15%," he added.

Global Stavudine Market Analysis (2019 - 2030)

Kotak Alternate Asset Managers (previously Kotak Investment Advisors), the alternative investment arm of Kotak Group, which hit a first close of its second special situation fund ......

The Andhra Pradesh-based infra major has a had a turbulent past; a port deal going back to 2012 landed it in a messy situation

/PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, announced today that its President, Rajiv Malik, will be retiring as an executive of...

Viatris Inc. announced that its President, Rajiv Malik, will be retiring as an executive of the Company effective April 1, 2024. Malik is a nearly 40-year pharmaceutical industry veteran who has been...

Kotak Strategic Situations Fund (KSSF) plans to invest around ₹1,600 crore in the active pharmaceutical ingredients (API) business acquired by Nimmagadda Prasad. The fund will support the acquisition through a $200 million funding, provided through a mix of structured debt and equity. Deutsche Bank and DBS have also reportedly financed the acquisition.

IQuest Enterprises has entered into a definitive agreement to acquire the API operations of global pharmaceutical major Viatris in India

Viatris Inc., the result of the merger between Mylan NV and Pfizer Inc.’s Upjohn unit in 2020, has sold two of its businesses in India ......